Unicycive Stock Dips After FDA CRL for Key Drug

Unicycive Therapeutics shares are trading lower after the FDA issued a Complete Response Letter for its New Drug Application for Oxylanthanum Carbonate, raising concerns over third-party manufacturing issues.